The Role of Echocardiography Screening at the Stroke Unit

Jorge Pagola¹,²*, Carlos Pagola³, Jesús Juega¹,², Teresa González-Alujas⁴, José Alvarez-Sabin¹,² and Carlos A. Molina¹,²

¹ Stroke Unit, Neurology Department, Vall D’Hebron Hospital, Vall D’Hebron Research Institute, Barcelona, Spain, ² Department of Medicine, Universitat Autònoma Barcelona, Barcelona, Spain, ³ Cardiology Department, Ciudad de Jaén University Hospital, Jaén, Spain, ⁴ Echocardiography Lab Cardiology Department, Vall D’Hebrón Hospital, CIBER-CV, Barcelona, Spain

Keywords: echocardiography, strain, PFO, TTE, POCUS, ventricle akinesia, cryptogenic stroke, complex aortic plaque

INTRODUCTION

Cardioembolic stroke is the most disabling cause of stroke and accounts for 30% of ischemic strokes (1, 2). The diagnosis is based on the identification of a potential cardiac source of embolism (SOE) (3). Transthoracic Echocardiogram (TTE) is a non-invasive, available and easy to perform technique to detect SOE with potential therapeutic implications (4, 5). The therapeutic yield of the TTE ranges from 2 to 37.2% depending on the age of the patients and previous heart disease (6, 7). A normal TTE decreases the yield of other advances techniques to detect SOE such as transesophageal echocardiogram (TEE) (8). TTE has been increasingly performed as part of stroke workup in the past few years, whereas TEE is used infrequently as screening test (9). More recently, Point of Care Ultrasound (POCUS) concept has increased its field of application and TTE as a screening method at the Stroke Unit is certainly under this rationale (10).

SUBSECTIONS RELEVANT FOR THE SUBJECT

The most frequent SOE are: atrial fibrillation (AF), left ventricle (LV) thrombus, endocarditis, prosthetic valves, and patent foramen ovale (PFO) (11). TTE contributes to the detection of these cardiac SOE as described below:

TTE—Atrial Fibrillation and Atrial Dysfunction

Every patient who has AF should undergo TTE study to find out the cause of the arrhythmia, which may range from non-cardiac causes (hyperthyroidism, alcoholism) to structural changes involving left atrial (LA) mitral stenosis. TTE will be of use in patients with previous AF and stroke to rule out subjacent valvular disease before the initiation of direct oral anticoagulants. Additionally, in cases of early recurrent embolism whether atrial thrombus is suspected. However, TTE has some difficulty evaluating the LA appendage where a thrombus may be lodged, although the development of real-time three-dimensional TTE can interrogate the LA appendage (12, 13).

It is unsustainable to provide prolonged monitoring to all patients. TTE can help select patients at risk of latent AF by the measurement of atrial dysfunction surrogates. Increased left atrial volume by TTE is one of these markers (14–16). Other TTE parameter related to development of AF is left atrial strain that assesses the left atria distensibility (17).

In recent years, the role of atrial dysfunction and atrial remodeling are being discussed as risk factors for further stroke in patients without AF. Accordingly, patients with severe LA enlargement (indicating atrial remodeling) are at risk of further ischemic stroke despite aspirin (18).
TTE—Left Ventricular Thrombus and Left Ventricular Dysfunction

The second most prevalent cause of cardioembolic stroke is LV akinesia related or not to LV thrombus (19, 20). TTE will easily detect LV akinesia of cardiac apex and anterior wall with 96% sensitivity and 90% specificity (21). The use of echocontrast can improve the visualization of hyperechogenic mass in at least two orthogonal views of an akinetic area (LV thrombus) (22). In addition, TTE can detect silent ischemic cardiomyopathy in patients with subclinical coronary disease who will require the attention of cardiologists.

Systolic dysfunction with EF < 30% is simply detectable with conventional software of TTE (Simpson formulae) and it is frequently associated with dilated cardiomyopathy (23).

TTE—PFO and Other Interatrial Changes

In young patients with cryptogenic stroke and a high Risk of Paradoxical Embolism (RoPE) score the presence of a PFO must be evaluated (24). TTE may detects certain normal anatomic variations of cardiac structures that may favor the formation of thrombi (25). The aneurysm of the interatrial septum, defined as >11 mm to >15 mm septum protrusion, is frequently associated with larger PFO (>4 mm size) and increases the risk of further stroke (26, 27). Other structures such as the persistence of the Eustachian valve that directs the blood flow to the PFO are visualized with ultrasound by contrast injection (28).

The Chiari’s network is a persistence of a remnant of the atrium formation that has been associated with thrombus creation (29). Finally, in patients with right atrial enlargement, interatrial communication may be suspected (30).

TTE and Aortic Plaques

Complex aortic plaque is a frequent cause of cryptogenic stroke in older patients (31, 32). Although TEE is the ultrasound modality of choice for the detection of aortic arch atheromatosis, many patients do not tolerate the test or they do not meet the cardiologist’s criteria for TEE. Aortic CT is a good alternative but it is not ideal to evaluate mobile thrombi (12). The aortic arch may be rapidly assessed in many patients with TTE from the suprasternal window (33). If a plaque larger than 4 mm size or mobile is detected the TEE can be performed earlier and focused on the area of greatest suspicion.

TTE and Valvulopathies

The prevalence of mitral stenosis secondary to rheumatic valvulopathies remains a major public health concern in low and middle-income countries (34). However, in our environment rheumatic valvulopathies has decreased dramatically and degenerative mitral stenosis related to older patients is the most common cause. The global prevalence of mitral stenosis has fallen and it is more common to find a patient with a mechanical prosthesis who has a stroke than a patient with classic mitral stenosis. After a stroke the chance of prosthetic valve thrombosis must be assessed. Mobility of the disks and transvalvular gradient could be evaluated by TTE; but in order to rule out non-obstructive thrombosis TEE must be performed. In a different scenario, when a patient with mechanical prosthesis has a cerebral hematoma, TTE may be useful to monitor the functionality of the prosthesis till the anticoagulants are resumed. Degenerative or rheumatic mitral stenosis can be detected with TTE and Doppler gradient by evaluating the thickening and the lack of mobility of the valves. In both native and mechanical valvulopathies, infective endocarditis is a possible cause of stroke. TTE plays a central role in detection of endocarditis; however, when suspected TEE is mandatory to determine the valve involvement and the characteristics of the vegetations (35). Equally, in order to diagnose non-bacterial thrombotic endocarditis (marantic endocarditis) TEE must be performed rather than TTE that may underdetect the vegetations (36).

Valvular and annular calcifications are associated with cover brain infarcts and cognitive decline (37). Some cases of embolization has been observed in mitral caseous degeneration that is detected by TTE as a large echogenic mass with a central echo-lucent area (38). Additionally, detection of aortic stenosis will be important to follow due to its poor prognosis in the long term.

TTE and Other Infrequent Causes

Cardiac tumors are a classic SOE. However, their frequency is so low (< 0.3%) that, in a suspicious image, we must first rule out the possibility of an artifact (some artifacts are only visualized in one plane but not in others) or, more rarely, a thrombus. Both thrombi and tumors have an erratic movement, unlike the cardiac structures (false tendons and trabeculations). When the movement is erratic the study should always be completed with TEE, and in many cases with cardiac MRI. Cardiac tumors most frequently associated with stroke are myxoma and fibroelastoma. Myxoma accounts for more than 50% of tumors (39). Its most common location is in the left atrium, while fibroelastoma is usually located in the aortic valve (40).

If we perform TTE in the first hours after the stroke, we can detect transient apical dyskinesia (Tako-tsubo cardiomyopathy). In order to be distinguished from ventricular akinesia by TTE one should observe a wall motion abnormality not restricted to a single coronary artery territory, affecting the mid-ventricular portions of the anterior, inferior, and lateral walls, in a circumferential configuration (41).

Non-compacted cardiomyopathy is an uncommon cause of stroke that is usually associated with systolic ventricular dysfunction (42). However, in initial stages it can cause embolisms without affecting the systolic function and should be suspected in case of multiple trabeculations with intertrabecular spaces in LV. In this case, once suspicion is made by TTE a cardiac MRI must confirm the diagnosis.

POINT OF CARE ULTRASOUND TO ASSESS SOE

In the last years, several protocols are being implemented to enhance the cost-effectiveness of TTE. One approach that will not require any advanced tools is Point of care ultrasound (POCUS). POCUS concept can be applied to the screening method of focused TTE on SOE detection, in neurologist’s
hands it decreased the length of stay and healthcare costs (43, 44). Indeed, a consensus Document on the recommendations and certifications to perform POCUS for non-cardiologists was published (45). Neurologists have better understood the functioning of cerebral hemodynamics since they have implemented the use of ultrasonography in their clinical practice. Patients admitted to the Stroke Unit often have hemodynamic instability. With POCUS we will evaluate the presence of significant ventricular hypertrophy which will guide us not to hyper hydrate the patient to avoid heart failure. In addition, in those patients in Shock, we can detect the collapse of the inferior vena cava to ascertain if the shock is due to heart failure. Although very rare, we can also detect pericardial effusion or pericardial tamponade in patients with heart failure or in shock.

**DISCUSSION**

Stroke Neurologists are experts in ultrasonography field so integrating POCUS into their stroke units makes sense, since 1 out of every 3 patients admitted to the Stroke Unit requires TTE. In regard to the prevalence of cardioembolic sources a rapid screening protocol can be drawn up according to the age of the patient and the presence of vascular risk factors. In TIA patients without vascular risk factors POCUS is less cost-effective. However, we can perform the POCUS in the first 24h after stroke in order to shorten diagnostic work-up duration to avoid overloading care and hospital stay (essential in times of pandemics).

In the first step of the screening with POCUS (Figure 1), viewing the ventricle, ventricular akinesia and/or severe systolic dysfunction will be detected just checking the movement of the LV. Similarly, mitral stenosis will be assessed by Doppler gradient and mobility of the valves.

If the function of the LV is normal, we will look at the aortic arch as detection of complex aortic plaques is frequent in elderly patients. If we detect a plaque larger than 4 millimeters size, we will request a TEE during admission to evaluate the presence of thrombus related to the complex plaque. Considering that the sensitivity of POCUS is not high, TEE will be required if the suspicion of embolic stroke is still there.

When none of the above provide any data, the size and characteristics of the LA can be checked. It is worth detecting the existence of A-wave pattern to uncover episodes of paroxysmal AF since the A wave is due to atrial contraction. Besides, if the volume of the LA is increased we can indicate intensive ambulatory cardiac monitoring to detect paroxysmal AF. Thus, we will increase the cost-effectiveness of POCUS.

In young patients a saline test with microbubbles can be performed to detect PFO by POCUS. Furthermore, POCUS will allow the evaluation of interatrial septal aneurysm, the Eustachian valve and/or the Chiari network in right atrium. Other anomalies such as cardiac tumor and mitral stenosis are very rare so we should not base the cost-effectiveness of the POCUS on their detection.

The yield of POCUS to detect SOE increases when patients with large vessel occlusion were examined in the first hours after the stroke onset (46).

---

**FIGURE 1 |** Screening protocol for patients with cardioembolic stroke suspicion. POCUS, point of care ultrasound; TEE, transesophageal echocardiogram.
The detection of SOE with POCUS has some limitations. Patients with high clinical suspicion for endocarditis (infective or non-bacterial) or mechanical prosthesis should undergo TEE in all cases. In addition, since the evaluation of segmental contractility changes is sometimes challenging, when POCUS is performed by neurologists it is advisable to seek the counsel of a cardiac imaging expert (47).

**CONCLUSION**

TTE remains as a useful technique to screen SOE. POCUS enhances the detection when performed by neurologists at stroke units.

**REFERENCES**

1. Ferro JM. Cardiogenic stroke: an update. *Lancet Neurol.* (2003) 2:177–88. doi: 10.1016/S1474-4422(03)00324-7
2. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* (2011) 42:517–84. doi: 10.1161/STR.0b013e3181fcb238
3. Nakanishi K, Homma S. Role of echocardiography in patients with stroke. *J Cardiovasc Med* (2016) 68:91–9. doi: 10.1016/j.jcc.2016.05.001
4. Morris JG, Duffis EJ, Fisher M. Cardiac workup of ischemic stroke: can we improve our diagnostic yield? *Stroke.* (2009) 40:2893–8. doi: 10.1161/STROKEAHA.109.551226
5. Saric M, Armour AC, Arnaout MS, Chaudhry FA, Grimm RA, Kronzon I, et al. Guidelines for the use of echocardiography in the evaluation of a cardiac source of embolism. *J Am Soc Echocardiogr.* (2016) 29:1–42. doi: 10.1016/j.echo.2015.09.011
6. Egebäck H, Andersen K, Hartliala J, Lindgren A, Marttila R, Petersen P, et al. Role of echocardiography in systemic arterial embolism. A review with recommendations. *Scand Cardiovasc J.* (1998) 32:323–42. doi: 10.1080/10474889809873780
7. Doufekias E, Segal AZ, Kizer JR. Cardiogenic and aortogenic brain embolism. *J Am Coll Cardiol.* (2008) 51:1049–59. doi: 10.1016/j.jacc.2007.11.053
8. Leung DY, Black IW, Cranney GB, Walsh WE, Grimm RA, Stewart WJ, et al. Selection of patients for transesophageal echocardiography after stroke and systemic embolic events. Role of transthoracic echocardiography. *Stroke.* (1995) 26:1820–4. doi: 10.1161/01.STR.26.10.1820
9. Giruparajah M, Bosch J, Vanassche T, Mattina K, Connolly SJ, Patel C, et al. Left atrial volume index is associated with cardioembolic stroke and atrial fibrillation detection after embolic stroke of undetermined source. *Stroke.* (2019) 50:1997–2001. doi: 10.1161/STROKEAHA.119.027235
10. Dietrich CF, Goudie A, Chiorean L, Cui XW, Gilja OH, Dong Y, et al. Point of care ultrasound: a WFUMB position paper. *Ultrasound Med Biol* (2015) 41:49–58. doi: 10.1016/ultrasmedbio.2016.06.021
11. Fonseca AG, Ferro JM. Cryptogenic stroke. *Eur J Neurol.* (2015) 22:618–23. doi: 10.1111/ene.12673
12. Camen S, Haeser LG, Schnabel RB. Cardiac imaging after ischemic stroke: echocardiography, CT, or MRI? *Herz.* (2019) 44:296–303. doi: 10.1007/s00505-019-4803-x
13. Ivataki M, Takeuchi M, Otani K, Kuwaki H, Haruki N, Yoshitani H, et al. Measurement of left atrial volume from transthoracic three-dimensional echocardiographic datasets using the biplane Simpson’s technique. *J Am Soc Echocardiogr.* (2012) 25:1319–26. doi: 10.1016/j.echo.2012.08.017
14. Prichett AM, Jacobsen SJ, Mahoney DW, Rodeheffer RJ, Bailey KR, Redfield MM. Left atrial volume as an index of left atrial size: a population-based study. *J Am Coll Cardiol.* (2003) 41:1036–43. doi: 10.1016/S0735-1097(02)02981-9
15. Jordan K, Yaghi S, Poppas A, Chang AD, Mac Gory B, Cutting S, et al. Left atrial volume index is associated with cardioembolic stroke and atrial fibrillation detection after embolic stroke of undetermined source. *Stroke.* (2019) 50:1997–2001. doi: 10.1161/STROKEAHA.119.027235
16. Tsang TS, Abhayaratna WP, Barnes ME, Miyasaka Y, Gersh BJ, Bailey KR, et al. Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter? *J Am Coll Cardiol.* (2006) 47:1018–23. doi: 10.1016/j.jacc.2005.08.077
17. Pagola J, González-Alujas T, Flores A, Muchada M, Rodríguez-Luna D, Soto L, et al. Left atria strain is a surrogate marker for detection of atrial fibrillation in cryptogenic strokes. *Stroke.* (2014) 45:e164–6. doi: 10.1161/STROKEAHA.114.005540
18. Healey JS, Gladstone DJ, Swaminathan B, Eckstein J, Mundi H, Epstein AE, et al. Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: secondary analysis of the NAVIGATE ESUS randomized clinical trial. *JAMA Neurol.* (2015) 72:674–70. doi: 10.1001/jamaneurol.2015.0617
19. Mooe T, Eriksson P, Stegmayr B. Ischemic stroke after acute myocardial infarction. A population-based study. *Stroke.* (1997) 28:762–7. doi: 10.1161/01.STR.28.4.762
20. Choi JY, Cha J, Jung JM, Seo WK, Oh K, Cho KH, et al. Left ventricular wall motion abnormalities are associated with stroke recurrence. *Neurology.* (2017) 88:586–94. doi: 10.1212/WNL.0000000000003588
21. Judgutt BI, Sivaram CA. Prospective two-dimensional echocardiographic evaluation of left ventricular thrombus and embolism after acute myocardial infarction. *J Am Coll Cardiol.* (1989) 13:554–64. doi: 10.1016/0735-1097(89)90592-5
22. Delewi R, Zijlstra F, Piek JJ. Left ventricular thrombus formation after acute myocardial infarction. *Heart.* (2012) 98:1743–9. doi: 10.1136/heartjnl-2012-301962
23. Kohsaka S, Sciacca RR, Sugioka K, Sacco RL, Homma S, Di Tullio MR. Additional impact of electrocardiographic over echocardiographic diagnosis of left ventricular hypertrophy for predicting the risk of ischemic stroke. *Am Heart J.* (2005) 149:181–6. doi: 10.1016/j.ahj.2004.06.006
24. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczak M, et al. Prevalence of patent foramen ovale in patients with stroke. *N Engl J Med.* (1988) 318:1148–52. doi: 10.1056/NEJM198805053181802
25. Koutroulou I, Tsivgoulis G, Tsalikakis D, Karacostas D, Grigorakis N, Karapanayiotides T. Epidemiology of patent foramen ovale in general population and in stroke patients: a narrative review. *Front Neurol.* (2020) 11:281. doi: 10.3389/fneur.2020.00281
26. Overell JR, Bone I, Lees KR. Intratral septal abnormalities and stroke: a meta-analysis of case-control studies. *Neurology.* (2000) 55:1172–9. doi: 10.1212/2585.8.1172
27. Mas JL, Derumeaux G, Guillou B, Massardier E, Hosseini H, Mechtouf L, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. *N Engl J Med.* (2017) 377:1011–21. doi: 10.1056/NEJMoa1705915
28. Schuchlenz HW, Sauer G, Wehns W, Rehak P. Persisting eustachian valve in adults: relation to patent foramen ovale and cerebrovascular events. *J Am Soc Echocardiogr.* (2004) 17:231–3. doi: 10.1016/j.echo.2003.12.003
29. Martínez-Quintana E, Rodríguez-González F. Chiari network and paradoxical embolism. *Rev Esp Cardiol.* (2015) 68:273. doi: 10.1016/j.rec.2014.09.018

**DISCLOSURE**

JP is the President of the Spanish Society of Neurosonology, the National Coordinator of POCUS certification for neurologists in Spain and one of the leaders of the Focused Echocardiography in Neurosonology group of the European Society of Neurosonology and Cerebral Hemodynamics.

**AUTHOR CONTRIBUTIONS**

JP design and conceptualized the manuscript. CP, JJ, TG-A, JA-S, and CM drafted the manuscript. All authors contributed to the article and approved the submitted version.
30. Smilowitz NR, Subashchandran V, Berger JS. Atrial septal defect and the risk of ischemic stroke in the perioperative period of noncardiac surgery. *Am J Cardiol.* (2019) 124:1120–8. doi: 10.1016/j.amjcard.2019.06.030

31. Ntaios G, Hart RG. Embolic stroke. *Circulation.* (2017) 136:2403–5. doi: 10.1161/CIRCULATIONAHA.117.030509

32. Amaresco P, Cohen A, Hommel M, Moulin T, Leys D, Bousser MG, et al. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. *N Engl J Med.* (1996) 334:1216–21. doi: 10.1056/NEJM199605093341902

33. Kronzon I, Tunick PA. Aortic atherosclerotic disease and stroke. *Circulation.* (2006) 114:63–75. doi: 10.1161/CIRCULATIONAHA.105.593418

34. Seckeler MD, Hoke TR. The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease. *Clin Epidemiol.* (2011) 3:67–84. doi: 10.2147/CLEP.S12977

35. Vilacosta I, Graupner C, San Román JA, Sarriá C, Ronderos R, Fernández C, et al. Risk of embolization after institution of antibiotic therapy for infective endocarditis. *J Am Coll Cardiol.* (2002) 39:1489–95. doi: 10.1016/S0735-1097(02)01790-4

36. Reisner SA, Brenner B, Haim N, Edoute Y, Markiewicz W. Echocardiography in nonbacterial thrombotic endocarditis: from autopsy to clinical entity. *J Am Soc Echocardiogr.* (2000) 13:876–81. doi: 10.1067/mje.2000.106070

37. Rodriguez CJ, Bartz TM, Longstreth WT, Kizer JR, Barash E, Lloyd-Jones DM, et al. Association of annular calcification and aortic valve sclerosis with brain findings on magnetic resonance imaging in community dwelling older adults: the cardiovascular health study. *J Am Coll Cardiol.* (2011) 57:2172–80. doi: 10.1016/j.jacc.2011.01.034

38. Chevalier B, Reant P, Lafitte S, Barandon L. Spontaneous fistulization of a caseous calcification of the mitral annulus: an exceptional cause of stroke. *Eur J Cardiothorac Surg.* (2011) 39:e184–5. doi: 10.1016/j.ejcts.2011.01.038

39. Reynen K. Cardiac myxomas. *N Engl J Med.* (1995) 333:1610–7. doi: 10.1056/NEJM1995121433332407

40. Sun JP, Asher CR, Yang XS, Cheng GG, Scala GM, Massed AG, et al. Clinical and echocardiographic characteristics of papillary fibroelastomas: a retrospective and prospective study in 162 patients. *Circulation.* (2001) 103:2687–93. doi: 10.1161/01.CIR.103.22.2687

41. Izumo M, Akashi YJ. Role of echocardiography for takotsubo cardiomyopathy: clinical and prognostic implications. *Cardiovasc Diagn Ther.* (2018) 8:90–100. doi: 10.21037/cdt.2017.07.03

42. Captur G, Ntaios G, Hart RG. Embolic stroke. *Circulation.* (2017) 136:2403–5. doi: 10.1161/CIRCULATIONAHA.117.030509

43. Amarenco P, Cohen A, Hommel M, Moulin T, Leys D, Bousser MG, et al. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. *N Engl J Med.* (1996) 334:1216–21. doi: 10.1056/NEJM199605093341902

44. Kronzon I, Tunick PA. Aortic atherosclerotic disease and stroke. *Circulation.* (2006) 114:63–75. doi: 10.1161/CIRCULATIONAHA.105.593418

45. Pagola J, González-Alujas T, Muchad M, Teixidó G, Flores A, De Blauwe S, et al. Stroke echoscan protocol: a fast and accurate pathway to diagnose embolic strokes. *J Neuroimaging.* (2015) 25:365–9. doi: 10.1111/jon.12139

46. Pérez de Isla L, Díaz Sánchez S, Pagola J, García de Cassola Sánchez G, López Fernández T, Sánchez Barrancos IM, et al. Consensus document of the SEMI, semFVC, SEN, and SEC on focused cardiac ultrasound in Spain. *Rev Esp Cardiol.* (2018) 71:935–40. doi: 10.1016/j.recesp.2018.05.027

47. Cullen MW, Blauwet LA, Vatury OM, Mulvagh SL, Behrenbeck TR, Scott CG, et al. Diagnostic capability of comprehensive handheld vs transthoracic echocardiography. *Mayo Clin Proc.* (2014) 89:790–8. doi: 10.1016/j.mayocp.2013.12.016

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Pagola, Pagola, Juega, González-Alujas, Alvarez-Sabin and Molina. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.